Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Granisetron
More News related to ABBI
- Abraxis Pharmaceutical Products (ABBI) Receives Two FDA Approvals
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Generic Camptosar Injection
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Granisetron
- Abraxis BioScience (ABBI) Tops Q2 EPS by 5c, Revs Light
- Abraxis BioScience (ABBI) Acquires Intellectual Property Rights for Technologies Designed to Discover New Drug Candidates from Buck Institute
More News related to FDA
- Mexican Restaurants (CASA) Posts Q3 Loss of $0.07, Better Y/Y; Revs Down
- Cosi (COSI) Posts Q3 Loss of $0.06, Beats By 2c
- Enterprise GP Holdings (EPE) Posts Q3 EPS of $0.18, Misses Views
- Mindray Medical (MR) Tops Q3 EPS by 6c; Revs Light
- Neenah Paper (NP) Tops Q3 Views
Abraxis BioScience, Inc. (NASDAQ: ABBI) received tentative approval from the FDA of its Abbreviated New Drug Application for Granisetron Hydrochloride Injection, 1 mg/mL, 1 mL vials, USP, the generic equivalent of Hoffmann-La Roche's Kytril Injection.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
